Myeloproliferative neoplasms (MPNs) are the most common cause of Budd-Chiari syndrome (BCS) and non-malignant, non-cirrhotic portal vein thrombosis (PVT). In this meta-analysis we determined the prevalence of MPNs and their subtypes as well as JAK2V617F and its diagnostic role in these uncommon disorders. MEDLINE and EMBASE databases were searched. Prevalence of MPNs, JAK2V617F and MPN subtypes were calculated using a random-effects model. A total of 1,062 BCS and 855 PVT patients were included. In BCS, mean prevalence of MPNs and JAK2V617F was 40.9% (95% CI: 32.9%-49.5%) and 41.1% (95%CI: 32.3%-50.6%), respectively. In PVT, mean prevalence of MPNs and JAK2V617F was 31.5% (95% CI: 25.1%-38.8%) and 27.7% (95%CI: 20.8%-35.8%), respectively. JAK2V617F and MPNs were more frequent in BCS compared to PVT (P=.03 and P=.09, respectively). Polycythemia vera was more prevalent in BCS than in PVT (P=.001).
INTRODUCTION
Splanchnic vein thrombosis (SVT) includes the Budd-Chiari syndrome (BCS) and portal vein thrombosis (PVT). Primary BCS is characterized by thrombosis of the hepatic veins and/or the suprahepatic inferior vena cava, resulting in obstruction of the hepatic venous outflow tract. 1 A distinct disorder that also includes the liver vasculature is portal vein thrombosis (PVT), which often occurs in association with local factors such as liver cirrhosis or malignancy. 2, 3 PVT in the absence of liver cirrhosis or local malignancy is less frequently encountered and shows a considerable overlap in etiology with primary BCS. In this metaanalysis, we will focus exclusively on primary BCS and non-malignant, non-cirrhotic PVT.
Philadelphia-negative myeloproliferative neoplasms (MPNs) are the most frequent underlying prothrombotic factor in BCS and PVT, with a reported prevalence of 30-50% [4] [5] [6] [7] [8] [9] and 15-30%, 2, 6, [10] [11] [12] respectively. Peripheral blood cell counts often remain within a normal range, due to portal hypertension and its sequelae (splenomegaly, hemodilution, iron deficiency). Despite suggestive features of an MPN, fulfilment of usual diagnostic criteria can therefore often be lacking, which is a notorious problem in MPN diagnostics in these patients.
The term occult MPN has been used in the literature for patients who lack these typical hematological features of MPN, but who harbour clear features of MPN, for example by means of bone marrow (BM) biopsy findings and growth of erythroid colonies in the absence of exogenous erythropoietin, referred to as spontaneous endogenous erythroid colonies (EEC), both of which have several limitations. [12] [13] [14] BM biopsy is invasive and the distinction between MPN and reactive BM is not unambiguous. EEC assays are performed only in specialized centers, are difficult to standardize and the possibility of false positives in nonclonal causes of erythrocytosis and healthy controls. 15 The discovery of the JAK2V617F gain-of-function mutation in 2005, found in 95% of patients with polycythemia vera (PV) and in about 50% of patients with essential thrombocythemia (ET) and myelofibrosis (MF), represented a crucial advance in the diagnostic approach to MPNs. [16] [17] [18] [19] The close relationship between MPNs and BCS and PVT The aims of this study were 1) to assess the prevalence of MPNs and JAK2V617F in BCS and PVT patients; 2) to determine the frequency of MPN subtypes in BCS and PVT patients; 3) to determine JAK2V617F prevalence in in BCS and PVT patients without typical hematological features of MPN, and; 4) to evaluate the clinical relevance of the MPL and JAK2 exon 12 mutations in BCS and PVT patients.
METHODS

Search strategy and selection criteria
One of the authors (J.S.) searched Ovid MEDLINE and EMBASE from 1980 to August 1 st 2011. The search strategy was restricted to published data and the English language using the subject headings presented in the appendix. The search was supplemented by manually reviewing the reference list of retrieved articles and relevant reviews. Titles and abstracts of retrieved citations were screened and potentially suitable studies were read in full by J.S. and F.L. Studies were selected when the following criteria were met: 1) patients were diagnosed with primary BCS or non-cirrhotic, non-malignant PVT, or patients with an underlying malignancy or cirrhosis were explicitly mentioned; 2) information on MPNs and/or 
Statistical analysis
Weighted mean proportion and 95% confidence intervals (CI) of MPNs, JAK2V617F, and MPN subtypes prevalence were calculated using a random effects model. Differences in prevalence were calculated by means of Pearson's chi square. All statistical tests were twosided and P-values < .05 were considered statistically significant. Statistical heterogeneity was evaluated using the I 2 statistic, which describes the percentage of variation across studies that is due to heterogeneity rather than chance, with a P-value < .05 representing statistically significant heterogeneity. If heterogeneity was present, the analyses were repeated removing one study a time to identify the source of heterogeneity. All analyses were performed with Comprehensive Meta Analysis 2.2 for Windows (Biostat, Englewood, USA) and the overall effects are presented as event rates with 95% CI.
RESULTS
Study identification and selection
We identified 822 potentially relevant publications: 256 from MEDLINE and 566 from EMBASE. A total of 109 studies were duplicate, and 665 studies were excluded after title and abstracts screening according to predefined inclusion criteria. The remaining studies were retrieved in full for detailed evaluation. Five additional studies were identified from reference lists. Figure 1 shows the study selection process.
Of the 53 retrieved studies, 21 were excluded because of the following reasons: in two studies patients with malignancies or liver cirrhosis were not excluded or explicitly mentioned, 30 14, [38] [39] [40] and two studies included less than 10 patients. 29, 41 In addition, seven studies contained duplicate data. [42] [43] [44] [45] [46] [47] [48] This resulted in 32 studies eligible for inclusion. One study described the long-term follow-up of 44 PVT patients with an underlying MPN. 64 For personal use only. on December 15, 2017. by guest www.bloodjournal.org From Five PV and two ET patients developed secondary MF, three patients with MF progressed to end-stage MF, and four patients developed acute myeloid leukemia after a median period of 9.7 years (range 1-17) following MPN diagnosis. Twenty-nine and 18% of the deaths in this cohort were attributable to end-stage MF and progression to acute myeloid leukemia, respectively.
Study characteristics and quality
JAK2 exon 12 and MPL515 mutations in splanchnic venous thrombosis
A total of 268 SVT patients (ratio BCS/PVT unknown) were tested for JAK2 exon 12 and 305 for MPL515 mutations. Three of these patients were found to carry MPLW515K mutation.
The JAK2 exon 12 mutation was not present in any of these patients.
Differences between BCS and PVT
Prevalence of JAK2V617F and MPNs was higher in BCS than in PVT (P = .03 and P = .09, respectively). With regards to the subtype analysis, prevalence of PV and MF was higher in BCS than in PVT patients (P = .001 and P = .09, respectively). Prevalence of solitary JAK2V617F positive MPNs was higher in PVT compared to BCS (P = .03). There was no difference between the prevalence of ET and MPNs unclassifiable (P = .77 and P = .92, respectively). There was no difference in identification rate of MPNs without typical features by means of JAK2V617F between the two disorders (17.1% vs. 15.4%, P = .68). All analyses were repeated including only publications since 2005 and excluding papers with potentially duplicated inclusion of patients, which showed the same results (data not shown).
I 2 and heterogeneity amongst studies
A considerable heterogeneity amongst the studies was observed (P < .05). We therefore performed an additional analysis in which we excluded one study per analysis. This analysis showed that no single study significantly affected the point estimate of MPNs, JAK2V617F and its subtypes in both BCS and PVT. and assessed its prevalence after exclusion of cases with pre-existing MPNs. 66 In contrast to those previously published studies, we set out to provide a complete overview of MPNs in the etiology of BCS and PVT. This included assessment of the prevalence of MPNs and JAK2V617F, as well as the prevalence of MPN subtypes. In addition, we have compared BCS and PVT for each of these variables, as it is increasingly recognized that, despite several similarities, risk profiles are different between these patients. 67 To achieve this goal, we have assessed all the publications regarding MPNs in SVT since 1980.
The results of this meta-analysis indicate a high prevalence of MPNs in patients with SVT. The strong relation between MPNs and SVT is confirmed by the high prevalence of JAK2V617F in these patients. Interestingly, JAK2V617F and MPNs were more prevalent in BCS compared to PVT patients, the latter showing a statistical trend rather than a significant difference. This difference may be partially explained by the more prominent role of local risk factors, such as focal inflammatory lesions and injury to the portal venous system, in the development of PVT. 68 This might contribute to the relatively limited role of general prothrombotic conditions reported in the etiology of PVT. Why MPNs and JAK2V617F are so strongly related to thrombosis of the splanchnic veins remains an unresolved issue. Further research is needed to identify associated factors that could be involved in the pathogenesis of thrombosis at these specific sites. In this respect, it has been speculated that endothelial cells of the splanchnic veins may interact with activated platelets and/or leukocytes and increased microparticles, which are characteristic features of MPNs. 69 In addition, these endothelial cells have been shown to carry the JAK2V617F mutation and could be part of the malignant process. 70 We observed a marked difference between BCS and PVT patients regarding the distribution of MPN subtypes. PV was clearly more common in BCS compared to PVT. The prothrombotic effect of high hematocrit values in PV is well established. 71 Under low-shear conditions, such as in the venous circulation, a high hematocrit has a more important impact on blood viscosity and causes a major disturbance to blood flow. 72, 73 This mechanism may be mediated by the interaction between adhesion molecules and red blood cells. Wautier et al described an increased adhesiveness of red blood cells in PV to human umbilical vein endothelial cells and elegantly showed that adhesion was inversely related to increasing shear stress, i.e. adhesion proved particularly increased at low shear rates. 9 It is possible that variability in the expression of these molecules along the vascular tree along with differences in flow conditions might contribute to the site-specificity of thrombosis, as suggested by these authors. 9 Indeed, the low-flow state in the hepatic veins compared to the portal venous system may participate in the higher frequency of PV in BCS. We also observed a statistical trend towards increased frequency of MF in PVT compared to BCS.
Such difference could be due to the frequent presence of splenomegaly in MF, which may lead to external compression of the portal venous system and subsequent stasis of blood This meta-analysis for the first time systematically assessed the diagnostic yield of JAK2V617F screening in SVT patients without typical hematological MPN features.
JAK2V617F screening identified MPN in 17.1% and 15.4% of these BCS and PVT patients, respectively, which would have remained undetected prior to the JAK2V617F era.
JAK2V617F was associated with subsequent development of MPNs with typical hematological MPN features in 41% and 14% of these BCS and PVT patients, respectively.
These findings clearly substantiate inclusion of JAK2V617F in the routine diagnostic work-up of all SVT patients, regardless of the absence of MPN hallmarks such as elevated peripheral blood cell counts. Whether MPN specific treatment should be initiated in these patients, such as cytoreductive therapies or addition of aspirin to oral anticoagulant treatment, is a question that remains to be answered. One study described the long-term outcome of PVT patients with an underlying MPN. 64 Twenty-nine and 18% of the deaths in this cohort were attributable to end-stage MF and progression to acute myeloid leukemia, respectively, indicating that risk of MPN progression is a clinical significant issue in these patients.
MPL515 mutations were reported in less than 1% of SVT patients, while the JAK2 exon 12 could not be found at all. The JAK2 exon 12 mutation has been described only once in both a PVT and BCS patient, but this was a case study. 29 These results indicate that both mutations are infrequent in SVT patients, in agreement with their low frequency in MPNs compared to the JAK2V617F mutation. [23] [24] [25] [26] [27] We therefore conclude that, unlike JAK2V617F, screening for these mutations is dispensable in the routine diagnostic approach of SVT patients.
Our analysis has several potential limitations. First, because of the rarity of both diseases, only observational studies have been published and could be included in this analysis, with their inherent risks of bias. However, a prospective design for rare thrombotic manifestations as PVT and BCS is probably unachievable. Second, a considerable heterogeneity amongst the included studies was noticed. We therefore performed all
For personal use only. on December 15, 2017. by guest www.bloodjournal.org From analyses using a random-effects model, thereby accounting for between study variance, next to within study variance. In addition to the random-effects analysis, which generates a conservative estimate, we performed an analysis in which we excluded one study at a time to assess its individual impact on the results. This analysis showed that none of the included studies significantly affected the estimated prevalence of MPNs, JAK2V617F, and its subtypes in both BCS and PVT. Third, diagnostic criteria for MPNs were not similar across studies. Notably, BM biopsy was not always routinely performed, which may have resulted in an underestimation of the prevalence of MPNs. Since this applies to both BCS and PVT series, the effect on the comparison between these two groups is presumably small, if at all present. Lastly, since the discovery of JAK2V617F in 2005, an increase in larger and better quality studies was observed. We therefore repeated all analyses including only publications from that point in time. In addition, we excluded papers with potential overlap of patients. The same differences between BCS and PVT were observed.
In conclusion, this meta-analysis shows a high prevalence of MPNs and JAK2V617F in SVT patients. Prevalence of JAK2V617F and MPNs in BCS are higher compared to PVT and differences in underlying MPN subtypes between these disorders exist. JAK2V617F screening identifies MPN in patients without typical hematological MPN features and should be included the routine diagnostic work-up of SVT. On the contrary, JAK2 exon 12 and MPL515 mutations are extremely rare in SVT and should not be used in the routine diagnostic approach of SVT patients. Altogether, our results are in line with the advancing insight that despite well-established similarities, marked differences in the etiology of BCS and PVT do exist.
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